CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blatt, C.
Right arrow Articles by Sachs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blatt, C.
Right arrow Articles by Sachs, L.

Cell Growth & Differentiation, Vol 3, Issue 10 671-676, Copyright © 1992 by American Association of Cancer Research


ARTICLES

Inhibition of specific pathways of myeloid cell differentiation by an activated Hox-2.4 homeobox gene

C Blatt, J Lotem and L Sachs
Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.

Abnormal expression of homeobox genes is one of the abnormalities associated with the development of murine and human leukemia. Myeloid leukemic cells that can be induced to differentiate to mature cells by interleukin 6 were stably transfected with an activated Hox-2.4 homeobox gene. Expression of the Hox-2.4 gene in the transfected clones inhibited specific pathways of the myeloid differentiation program induced by interleukin 6. The expression of some genes associated with differentiation was almost completely blocked, and the expression of other genes was either partially inhibited or not affected. The results support the hypothesis that abnormal expression of Hox-2.4 may contribute to the development of leukemia by interfering with the differentiation program.


This article has been cited by other articles:


Home page
Sci. Immunol.Home page
P. Y. Lee, D. B. Sykes, S. Ameri, D. Kalaitzidis, J. F. Charles, N. Nelson-Maney, K. Wei, P. Cunin, A. Morris, A. E. Cardona, et al.
The metabolic regulator mTORC1 controls terminal myeloid differentiation
immunology, May 26, 2017; 2(11): eaam6641 - eaam6641.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. J. Nemeth, D. J. Curtis, M. R. Kirby, L. J. Garrett-Beal, N. E. Seidel, A. P. Cline, and D. M. Bodine
Hmgb3: an HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation
Blood, August 15, 2003; 102(4): 1298 - 1306.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood, May 15, 1999; 93(10): 3167 - 3215.
[Full Text] [PDF]


Home page
J Biol ChemHome page
Q. Pan and R. U. Simpson
c-myc Intron Element-binding Proteins Are Required for 1,25-Dihydroxyvitamin D3 Regulation of c-myc during HL-60 Cell Differentiation and the Involvement of HOXB4
J. Biol. Chem., March 26, 1999; 274(13): 8437 - 8444.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1992 by the American Association of Cancer Research.